As of Feb 26
| +0.01 / +0.16%|
The 6 analysts offering 12-month price forecasts for Conatus Pharmaceuticals Inc have a median target of 13.50, with a high estimate of 17.00 and a low estimate of 6.00. The median estimate represents a +108.98% increase from the last price of 6.46.
The current consensus among 6 polled investment analysts is to Buy stock in Conatus Pharmaceuticals Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.